A new era for myasthenia gravis: FcRn and complement inhibitors are changing the game

Treating generalized myasthenia gravis (gMG) has undergone a dramatic transformation since the first complement inhibitor hit the market in 2017. In a post-forum interview, Dr. Shaida Khan of UT Southwestern Medical Center reflected on how FcRn and complement inhibitors have reshaped the treatment landscape — offering faster-acting, safer, and more targeted options for patients with AChR and MuSK antibody-positive gMG. Clinicians now have far less tolerance for prolonged courses of older immunosuppressants and steroids, and are increasingly willing to reach for newer agents earlier in the disease course.

Looking ahead, Dr. Khan is excited about the potential for biomarkers — such as microRNA profiles and IgG levels — to guide more personalized treatment decisions, including the possibility of safely de-escalating or even discontinuing therapy in select patients. She draws a parallel to the multiple sclerosis field, where precision medicine has already transformed care, and expects gMG to follow a similar trajectory.

Key Takeaways

• FcRn and complement inhibitors are increasingly being considered as first-line options in certain gMG patient populations
• Updated consensus guidelines are expected to place complement inhibitors at the forefront of treatment algorithms
• Several new therapies are in Phase 2 and Phase 3 trials, with approvals anticipated in the coming years
• Biomarker-driven treatment selection and de-escalation strategies represent a major unmet need and active area of research

Why it matters: For neurologists managing gMG, the shift toward earlier use of targeted therapies — and the promise of precision medicine on the horizon — means patients may achieve remission faster and with fewer side effects than ever before.